Ulcer healing in diabetic rats treated with aspirin, nitric oxide (NO)-derivative of aspirin and COX-2 inhibitor

被引：0
|
作者：
Brzozowski, T
Konturek, PC
Sliwowski, Z
Pawlik, M
Stachura, J
Konturek, SJ
Jaworek, J
Pawlik, WW
Hahn, EG
机构：
来源：
GASTROENTEROLOGY | 2003年 / 124卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(03)80850-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A171 / A171
页数：1
相关论文
共 50 条
  • [1] Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor
    Brzozowska, I
    Targosz, A
    Sliwowski, Z
    Kwiecien, S
    Drozdowicz, D
    Pajdo, R
    Konturek, PC
    Brzozowski, T
    Pawlik, M
    Konturek, SJ
    Pawlik, WW
    Hahn, EG
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2004, 55 (04): : 773 - 790
  • [2] Helicobacter pylori attenuates the delay in ulcer healing induced by aspirin and selective COX-2 inhibitor
    Brzozowski T.
    Konturek P.C.
    Sliwowski Z.
    Konturek S.
    Bielanski W.
    Pajdo R.
    Drozdowicz D.
    Hahn E.
    InflammoPharmacology, 2002, 10 (4-6) : 423 - 433
  • [3] NO releasing aspirin (ASA) fails to impair ulcer healing in diabetic rats due to the reversal of the fall in ghrelin, leptin and COX-2 expression
    Konturek, PC
    Brzozowski, T
    Kukharskyy, V
    Bazela, K
    Pajdo, R
    Pawlik, WW
    Hahn, EG
    Konturek, SJ
    GASTROENTEROLOGY, 2004, 126 (04) : A614 - A614
  • [4] Differences in inhibition of aberrant crypt foci in rats treated with aspirin, an aspirin nitric oxide-releasing derivative or lysin acetylsalicylate (LAS).
    Benamouzig, R
    Brezault-Bonnet, C
    Bertrand, V
    Meziani, K
    Martin, A
    Couturier, D
    Rautureau, J
    Chaussade, S
    GASTROENTEROLOGY, 1999, 116 (04) : A377 - A377
  • [5] Safety of a specific COX-2 inhibitor in aspirin-induced asthma
    Szczeklik, A
    Nizankowska, E
    Bochenek, G
    Nagraba, K
    Mejza, F
    Swierczynska, M
    CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (02): : 219 - 225
  • [6] Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors
    Renda, Giulia
    Zurro, Maria
    Romano, Mario
    De Caterina, Raffaele
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (03) : 303 - 306
  • [7] Major GI events among cox-2 inhibitor, NSAID, and aspirin users
    Mullins, CD
    Tran, BV
    Shaya, FT
    Naradzay, JF
    Howard, KB
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S271 - S272
  • [8] Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer
    Ng, Kimmie
    Meyerhardt, Jeffrey A.
    Chan, Andrew T.
    Sato, Kaori
    Chan, Jennifer A.
    Niedzwiecki, Donna
    Saltz, Leonard B.
    Mayer, Robert J.
    Benson, Al B., III
    Schaefer, Paul L.
    Whittom, Renaud
    Hantel, Alexander
    Goldberg, Richard M.
    Venook, Alan P.
    Ogino, Shuji
    Giovannucci, Edward L.
    Fuchs, Charles S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (01):
  • [9] Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: Comparison with plain aspirin
    Takeuchi, K
    Ukawa, H
    Konaka, A
    Kitamura, M
    Sugawa, Y
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 286 (01): : 115 - 121
  • [10] Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis
    Malgorzata Zwolinska-Wcislo
    Tomasz Brzozowski
    Agata Ptak-Belowska
    Aneta Targosz
    Katarzyna Urbanczyk
    Slawomir Kwiecien
    Zbigniew Sliwowski
    World Journal of Gastroenterology, 2011, 17 (36) : 4076 - 4089
12345